Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense(R) As Treatment For Chronic Lymphocytic Leukemia

... GentaIncorporated (Nasdaq: GNTA) announced that the Company has been notified by the Food and Drug Administration (FDA) that the Oncology Drug AdvisoryCommittee (ODAC) will review the New Drug Application (NDA) forGenasense(R) (oblimersen sodium) Injection plus chemotherapy for thetreatment of patients with relapsed or refractory chronic lymphocyticleukemia (CLL) on September 6, 2006. [click link for full article] ...